This menu provides the list of EV proteins identified by high-throughput analyses.

Search:
Superdomain: All Prokaryote Eukaryote
Filter datasets:
  - "Sample type" indicates the source from which EVs originated (e.g. B cell, serum).
  - "Sample status" indicates the condition of the source from which EVs originated (e.g. Normal, miR-146a-treated, Patients of hernia).
Number of molecules in one page:

The downloaded CSV file is not exactly the same as the displayed table. Opening CSV file with Excel can impair its content.

Protein name UniProt accession Publication Orthologous group Identification count
All / Prokaryote / Eukaryote
Keratin, type II cytoskeletal 6A (Cytokeratin-6A) (CK-6A) (Keratin-6-alpha) (mK6-alpha) (Keratin-6A) (K6A)P50446Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells.
Nat Cell Biol. 2007 Jun;9(6):654-9. Epub 2007 May 7.		ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6A (Cytokeratin-6A) (CK-6A) (Keratin-6-alpha) (mK6-alpha) (Keratin-6A) (K6A)P50446Oligodendrocytes secrete exosomes containing major myelin and stress-protective proteins: Trophic support for axons?
Proteomics Clin Appl. 2007 Nov;1(11):1446-61. doi: 10.1002/prca.200700522. Epub 2007 Oct 16.		ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6A (Cytokeratin-6A) (CK-6A) (Keratin-6-alpha) (mK6-alpha) (Keratin-6A) (K6A)P50446Exosomes from Plasmodium yoelii-infected reticulocytes protect mice from lethal infections.
PLoS One. 2011;6(10):e26588. doi: 10.1371/journal.pone.0026588. Epub 2011 Oct 26.		ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6A (Cytokeratin-6A) (CK-6A) (Keratin-6-alpha) (mK6-alpha) (Keratin-6A) (K6A)P50446Circulating Extracellular Vesicles with Specific Proteome and Liver MicroRNAs Are Potential Biomarkers for Liver Injury in Experimental Fatty Liver Disease.
PLoS One. 2014 Dec 3;9(12):e113651. doi: 10.1371/journal.pone.0113651. eCollection 2014.		ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6A (Cytokeratin-6A) (CK-6A) (Keratin-6-alpha) (mK6-alpha) (Keratin-6A) (K6A)P50446Membrane microvesicles as mediators for melanoma-fibroblasts communication: Roles of the VCAM-1/VLA-4 axis and the ERK1/2 signal pathway.
Cancer Lett. 2015 Feb 4. pii: S0304-3835(15)00066-X. doi: 10.1016/j.canlet.2015.01.032.		ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6A (Cytokeratin-6A) (CK-6A) (Keratin-6-alpha) (mK6-alpha) (Keratin-6A) (K6A)P50446Cells release subpopulations of exosomes with distinct molecular and biological properties.
Sci Rep. 2016 Mar 2;6:22519. doi: 10.1038/srep22519.		ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6A (Cytokeratin-6A) (CK-6A) (Keratin-6-alpha) (mK6-alpha) (Keratin-6A) (K6A)P50446Cells release subpopulations of exosomes with distinct molecular and biological properties.
Sci Rep. 2016 Mar 2;6:22519. doi: 10.1038/srep22519.		ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6A (Cytokeratin-6A) (CK-6A) (Keratin-6-alpha) (mK6-alpha) (Keratin-6A) (K6A)P50446Cells release subpopulations of exosomes with distinct molecular and biological properties.
Sci Rep. 2016 Mar 2;6:22519. doi: 10.1038/srep22519.		ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6A (Cytokeratin-6A) (CK-6A) (Keratin-6-alpha) (mK6-alpha) (Keratin-6A) (K6A)P50446Microvesicles provide a mechanism for intercellular communication by embryonic stem cells during embryo implantation.
Nat Commun. 2016 Jun 15;7:11958. doi: 10.1038/ncomms11958.		ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6A (Cytokeratin-6A) (CK-6A) (Keratin-6-alpha) (mK6-alpha) (Keratin-6A) (K6A)P50446Thymic exosomes promote the final maturation of thymocytes.
Sci Rep. 2016 Nov 8;6:36479. doi: 10.1038/srep36479.		ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6A (Cytokeratin-6A) (CK-6A) (Keratin-6-alpha) (mK6-alpha) (Keratin-6A) (K6A)P50446The Hippo Pathway Kinases LATS1/2 Suppress Cancer Immunity.
Cell. 2016 Dec 1;167(6):1525-1539.e17. doi: 10.1016/j.cell.2016.11.005.		ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6A (Cytokeratin-6A) (CK-6A) (Keratin-6-alpha) (mK6-alpha) (Keratin-6A) (K6A)P50446The Hippo Pathway Kinases LATS1/2 Suppress Cancer Immunity.
Cell. 2016 Dec 1;167(6):1525-1539.e17. doi: 10.1016/j.cell.2016.11.005.		ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6A (Cytokeratin-6A) (CK-6A) (Keratin-6-alpha) (mK6-alpha) (Keratin-6A) (K6A)P50446Exploring experimental cerebral malaria pathogenesis through the characterisation of host-derived plasma microparticle protein content.
Sci Rep. 2016 Dec 5;6:37871. doi: 10.1038/srep37871.		ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6A (Cytokeratin-6A) (CK-6A) (Keratin-6-alpha) (mK6-alpha) (Keratin-6A) (K6A)P50446Astrocyte-shed extracellular vesicles regulate the peripheral leukocyte response to inflammatory brain lesions.
Sci Signal. 2017 Apr 4;10(473). pii: eaai7696. doi: 10.1126/scisignal.aai7696.		ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6A (Cytokeratin-6A) (CK-6A) (Keratin-6-alpha) (mK6-alpha) (Keratin-6A) (K6A)P50446Astrocyte-shed extracellular vesicles regulate the peripheral leukocyte response to inflammatory brain lesions.
Sci Signal. 2017 Apr 4;10(473). pii: eaai7696. doi: 10.1126/scisignal.aai7696.		ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6A (Cytokeratin-6A) (CK-6A) (Keratin-6-alpha) (mK6-alpha) (Keratin-6A) (K6A)P50446Hypoxia-induced changes in the fibroblast secretome, exosome, and whole-cell proteome using cultured, cardiac-derived cells isolated from neonatal mice.
J Proteome Res. 2017 Jun 22. doi: 10.1021/acs.jproteome.7b00144.		ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6A (Cytokeratin-6A) (CK-6A) (Keratin-6-alpha) (mK6-alpha) (Keratin-6A) (K6A)P50446Hypoxia-induced changes in the fibroblast secretome, exosome, and whole-cell proteome using cultured, cardiac-derived cells isolated from neonatal mice.
J Proteome Res. 2017 Jun 22. doi: 10.1021/acs.jproteome.7b00144.		ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6A (Cytokeratin-6A) (CK-6A) (Keratin-6-alpha) (mK6-alpha) (Keratin-6A) (K6A)P50446Extracellular vesicles released by cardiomyocytes in a doxorubicin-induced cardiac injury mouse model contain protein biomarkers of early cardiac injury.
Clin Cancer Res. 2017 Oct 25. pii: clincanres.2046.2017. doi: 10.1158/1078-0432.CCR-17-2046.		ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6A (Cytokeratin-6A) (CK-6A) (Keratin-6-alpha) (mK6-alpha) (Keratin-6A) (K6A)P50446Extracellular vesicles released by cardiomyocytes in a doxorubicin-induced cardiac injury mouse model contain protein biomarkers of early cardiac injury.
Clin Cancer Res. 2017 Oct 25. pii: clincanres.2046.2017. doi: 10.1158/1078-0432.CCR-17-2046.		ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6A (Cytokeratin-6A) (CK-6A) (Keratin-6-alpha) (mK6-alpha) (Keratin-6A) (K6A)P50446Proteomic profiling of exosomes secreted by breast cancer cells with varying metastatic potential.
Proteomics. 2017 Nov 8. doi: 10.1002/pmic.201600370.		ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6A (Cytokeratin-6A) (CK-6A) (Keratin-6-alpha) (mK6-alpha) (Keratin-6A) (K6A)P50446Proteomic profiling of exosomes secreted by breast cancer cells with varying metastatic potential.
Proteomics. 2017 Nov 8. doi: 10.1002/pmic.201600370.		ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6A (Cytokeratin-6A) (CK-6A) (Keratin-6-alpha) (mK6-alpha) (Keratin-6A) (K6A)P50446Proteomic profiling of exosomes secreted by breast cancer cells with varying metastatic potential.
Proteomics. 2017 Nov 8. doi: 10.1002/pmic.201600370.		ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6A (Cytokeratin-6A) (CK-6A) (Keratin-6-alpha) (mK6-alpha) (Keratin-6A) (K6A)P50446Proteomic profiling of exosomes secreted by breast cancer cells with varying metastatic potential.
Proteomics. 2017 Nov 8. doi: 10.1002/pmic.201600370.		ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6A (Cytokeratin-6A) (CK-6A) (Keratin-6-alpha) (mK6-alpha) (Keratin-6A) (K6A)P50446Differential content of proteins, mRNAs, and miRNAs suggests that MDSC and their exosomes may mediate distinct immune suppressive functions.
J Proteome Res. 2017 Nov 15. doi: 10.1021/acs.jproteome.7b00646.		ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6A (Cytokeratin-6A) (CK-6A) (Keratin-6-alpha) (mK6-alpha) (Keratin-6A) (K6A)P50446Differential content of proteins, mRNAs, and miRNAs suggests that MDSC and their exosomes may mediate distinct immune suppressive functions.
J Proteome Res. 2017 Nov 15. doi: 10.1021/acs.jproteome.7b00646.		ENOG410YY6B437 / 0 / 437
Keratin, type II cytoskeletal 6A (Cytokeratin-6A) (CK-6A) (Keratin-6-alpha) (mK6-alpha) (Keratin-6A) (K6A)P50446Exosomes as secondary inductive signals involved in kidney organogenesis.
J Extracell Vesicles. 2018 Jan 23;7(1):1422675. doi: 10.1080/20013078.2017.1422675. eCollection 2018.		ENOG410YY6B437 / 0 / 437
[1]